golf, even though the SUSTAIN and ASSURE phase 2b trials overall data showed that RVX-208 raises ApoA-I/HDL and represses pro-inflammatory, pro-atherosclerotic and pro-thrombotic pathways that can contribute to CVD risk, this is not enough to market apabetalone on its own for this specific health benefit. Crazy eh!
Koo